Methods of treating cancer with HDAC inhibitors

An inhibitor and dosage technology, applied in the direction of anhydride/acid/halide active ingredients, etc., can solve the problem of not disclosing favorable pharmacokinetic characteristics, etc.
CN1870985AInactive Publication Date: 2006-11-29MERCK HDAC RESEARCH LLC +1
24 Cites 10 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
MERCK HDAC RESEARCH LLC
Publication Date
2006-11-29
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates to methods of treating cancers, e.g., mesothelioma or lymphoma. More specifically, the present invention relates to methods of treating mesothelioma or diffuse large B-cell lymphoma (DLBCL), by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Statement of Government Interests

[0002] This invention was made in whole or in part with government support provided by the National Cancer Institute under grant number 1R21CA 096228-01. The government may have certain rights in this invention. field of invention

[0003] The present invention relates to methods of treating cancer such as mesothelioma or lymphoma. More specifically, the present invention relates to the treatment of mesothelioma, diffuse large B-cell lymphoma (DLBCL) by administering a pharmaceutical composition comprising an HDAC inhibitor such as suberoylanilide hydroxamic acid (SAHA). ) or other cancer or tumor methods. Oral formulations of these pharmaceutical compositions have favorable pharmacokinetic characteristics such as high bioavailability and unexpectedly result in high blood levels of the active compound over prolonged periods of time. Background of the invention [000...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More